The paper by La Vague and Rossiter recommends that placebo-controlled trial
s only be conducted when "best proven" treatments are not available. In thi
s comment, I review evidence suggesting that identifying "best proven" trea
tments is a complex task involving many variables and that making such a de
cision entails many real-world difficulties.